Activartis Receives Orphan Drug Designation for its Cancer Immune Therapy AV0113
The European Medicines Agency recently awarded the Austrian biotech company Activartis an Orphan Drug Designation for its innovative Cancer Immune Therapy AV0113
Vienna, Austria, March 7, 2013 / B3C newswire / - The European Medicines Agency recently awarded the Austrian biotech company ctivartis an Orphan Drug Designation for its innovative Cancer Immune Therapy AV0113. The Orphan Drug Designation applies specifically to the use of AV0113 for the treatment of glioma, a type of brain tumour, which afflicts around one in 10.000 people in the EU. The term Orphan Disease refers to rare diseases which do not attract much interest in the way of research and development and thus for which there are no appropriate treatments available.
Activartis’ AV0113 Cancer Immune Therapy can basically be used to fight every type of cancer. The therapeutic technology is based on a patented procedure in which a cancer patient’s immune system is primed to fight the tumour and eventually control its growth. This is based on the use of Dendritic Cells, the key regulatory elements of the immune system, that are just as the tumour tissue derived from the patient.
Active cancer immune therapy based on Dendritic Cells
AV0113 activates the patient’s immune system, with tumour cells being identified on the basis of their antigens and destroyed. The therapy makes use of elements and mechanisms of the immune system and gets to work where these fail. As tumour cells are the body’s own tissue, the immune system normally doesn’t identify them as dangerous. Activartis’ AV0113 Cancer Immune Therapy “tricks” Dendritic Cells, and onsequently a cancer patient’s immune system, into doing the right thing, i.e. to perceive the tumour as a threat and to trigger adequate defence mechanisms.
The Dendritic Cells are charged with tumour-derived antigens, determinants that distinguish a tumour cell from a normal cell. These antigens are processed by the Dendritic Cell and shuttled to the cell surface in order to present them to T-cells. This, however, is not sufficient to prime an immune response against the tumour antigens. The “trick” referred to above is contacting Dendritic Cells with a microbial danger signal. Certain molecules, that are present in microorganisms but not in higher organisms signal the Dendritic Cell the presence of a microorganism in its surroundings and hence danger to the organism.
As tumour cells originate from a cancer patient’s normal cells, they do not provide such danger molecules for recognition by the Dendritic Cell. The critical and unique part of Activartis’ AV0113 technology is exposing tumour antigen-charged Dendritic Cells to one of these danger molecules: Lipopolysaccharides, the bacterial endotoxins. This causes the Dendritic Cell to assume a potently immune stimulatory and
pro-inflammatory mode of action. Upon returning these Dendritic Cells to the patient they activate tumour-specific T-cells, most importantly the so-called Cytotoxic T-cells, which become enabled to recognise and destroy tumour cells
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance